FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Olaparib (LYNPARZA®) Capsules
Status: Discontinuation
»Therapeutic Categories: Oncology

AstraZeneca (New 08/28/2018)

Company Contact Information:
800-236-9933

Presentation Posting Date Related Information
50 mg capsules for oral use; bottles of 112 capsules (NDC 0310-0657-58) N/A The planned permanent discontinuation of olaparib capsules from the U.S. market is August 31, 2018. Two other options available for olaparib (LYNPARZA®): Tablets, 150 mg: green to green/grey, oval, bi-convex, film-coated tablet, are available in: Bottles of 60 tablets (NDC 0310-0679-60) and Bottles of 120 tablets (NDC 0310-0679-12). Tablets, 100 mg: yellow to dark yellow, oval, bi-convex, film-coated tablet, are available in: Bottles of 60 tablets (NDC 0310-0668-60) and Bottles of 120 tablets (NDC 0310-0668-12).

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English